BioCardia Narrows Loss in Fiscal Q2
BioCardia (NASDAQ:BCDA), a clinical-stage cell therapy company focused on treatments for heart disease, released its financial results for the second quarter of 2025 on August 11, 2025. The company reported no revenue for the period and a net loss per share of $(0.40) (GAAP), narrower than the estimated loss of $(0.50). The quarter was marked by sharply higher research and development costs, declining assets, cash constraints, and steady progress in its pipeline of cell-based therapeutics. While the financial results reflected the typical pressures seen in pre-commercial biotech firms, the company made clinical progress in its core cardiovascular programs and advanced regulatory submissions both in the United States and Japan.
Source: Analyst estimates for the quarter provided by FactSet.
BioCardia specializes in regenerative medicine for cardiovascular diseases, developing cell therapy platforms to treat heart failure and chronic myocardial ischemia. Its key assets include the CardiAMP autologous cell therapy system for ischemic heart failure and chronic myocardial ischemia, CardiALLO allogeneic mesenchymal stem cell therapy, and biotherapeutic delivery devices such as the Helix system.
Source Fool.com
